Themis Bioscience completes Series A Financing round – EUR 5 Million to advance promising vaccine candidates

Vienna, 18. May 2011

Themis Bioscience GmbH (, an Austrian start-up biotechnology company developing novel vaccines against emerging infectious diseases with high unmet medical need announced today the closing of a EUR 5 Million Series A Financing round co-led by the international venture capital funds Ventech and Crédit Agricole Private Equity. The investment will be used to expedite the pre-­‐clinical and clinical development activities for Themis’ lead product candidates, a Dengue and a Chikungunya Fever vaccine. Both vaccine candidates have demonstrated promising preclinical data. They are based on a novel vaccine vector technology that was initially developed at the Institut Pasteur in Paris, with which Themis collaborates.

“We are delighted to welcome Ventech and Crédit Agricole as investors in our company. This investment will allow us to move our development projects forward at full speed and to demonstrate clinical proof-of-concept”, states Erich Tauber, CEO of Themis Bioscience. “We are convinced that Themis and its technology platform have great potential to deliver very promising vaccine candidates that will already at early clinical stage put the company into an ideal position to become an attractive licensing partner for major pharmaceutical companies”, commented Karl Naegler, General Partner at Ventech. “Themis is to develop a new generation of vaccines for emerging diseases, based on a highly promising technology and an experienced core team” adds Bruno Montanari, Director at Crédit Agricole Private Equity’s Venture Capital team.

Themis Bioscience was founded in Vienna in 2009 and received seed financing by the academic business incubator INiTS, the austria wirtschaftsservice (aws) and The Austrian Research Promotion Agency (FFG).

About Themis
The Vaccine Innovation Boutique Themis Bioscience is a start‐up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late‐stage clinical development phases. The company aims to exploit the increasing licensing and acquisition trend on the vaccine market to generate value by developing and partnering its technology programs and vaccine candidates. Themis’ core lead technology, Themaxyn™ ‐ a highly novel, patent‐protected, and innovative vaccine platform which originates from the world‐leading Institut Pasteur ‐ will be used to create novel vaccines. The Company’s first vaccine targets are emerging tropical and travelers diseases, including dengue, chikungunya and yellow fever virus, and there is clear potential to expand the Themaxyn™ technology to further indications. Themis was founded in September 2009 and is based in Vienna, Austria. Please be invited to for more detailed information.

About dengue virus and chikungunya virus
Dengue fever is transmitted by various mosquitoes of the genus Aedes, carrying the dengue virus. The first documented epidemic occurred from 1779 to 1780 simultaneously in Asia, Africa and North America, demonstrating a worldwide distribution of at least 200 years. The rapid population growth, urbanization and international air traffic have contributed to a dramatic increase in dengue disease in recent years.  Today more than 2.5 billion people live in risk areas in the tropics and subtropics. The WHO estimates 50 to 100 million illnesses annually, of which 250,000 to 500,000 represent the severe form, dengue haemorrhagic fever (DHF). Currently, there is no preventive vaccine or specific therapy.

Chikungunya fever is a viral infection and is also transmitted by mosquitoes of the genus Aedes. This viral pathogen occurs in South and Southeast Asia, and in Africa south of the Sahara, but of note is especially a recent epidemic in Italy. Symptoms
include a sudden onset of high fever, headache, conjunctivitis and muscle and joint pian and arthralgia. Currently, there is no preventive vaccine  or specific therapy.

About Ventech
Ventech is a venture capital company which has invested for over 10 years in innovative IT and Life Sciences companies. Investments under management total over 360 million euros. Ventech’s was initially focused on investments in the Paris region but has established a presence in China. In Life Sciences, the company is focused on Europe and the US, especially in medical research, diagnostics, and medical devices. Further information is available at

About Crédit Agricole Private Equity
Crédit Agricole Private Equity is an AMF‐accredited asset‐management subsidiary of Crédit Agricole, specialising in direct private‐equity investment in non‐listed companies. As multi‐specialist player, Crédit Agricole Private Equity’s team of 100 professionals manages €3.3 billion with specific expertise in LBO & Expansion, Venture Capital, Mezzanine, Co‐Investment, Renewable Energy and PPP Infrastructure. The 11‐strong venture capital team manages €470 million through FCPIs invested in young companies with high growth potential in 2 sectors: information technology and life sciences.

Crédit Agricole Private Equity has signed up to the United Nations’ Principles for Responsible Investment (PRI).­‐

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)